Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
doi: 10.1056/NEJMoa2206038 119 AdriaenssensAEBiggsEKDarwishTTadrossJSukthankarTGirishMet al
As expected, positive control analyses showed lower risks of major adverse cardiovascular events and major adverse kidney events among GLP-1 RA initiators relative to DPP-4i initiators, whereas negative control outcomes (glaucoma and bone fracture) did not differ between groups ( Supplementary Table 2 )
162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction
One vial, properly stored and used within its expiration window, can last months at microdose levels (though the 28-day beyond-use date means you will still need fresh vials regularly)
